Vertex Pharmaceuticals Incorporated (VRTX) Insider Trading

Last 12 months

Insiders sold $158M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Aug 2025.

Net open-market

−$158M

0 buys · 52 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 13

executives and directors

Last open-market buy

Aug 2025

Aug 6, 2025

Get an email when VRTX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jul 2	Ourania Tatsis EVP, Chief Reg. & Quality Off.	Sold10b5-1 plan	1,500	$524.99	$787k	3.2%	Form 4
Jul 2	Duncan McKechnie EVP, Chief Commercial Officer	Sold10b5-1 plan	1,541	$519.00	$800k	12%	Form 4
Jul 1	Joy Liu EVP and Chief Legal Officer	Sold10b5-1 plan	828	$502.71	$416k	4.1%	Form 4
Jun 26	Carmen Bozic EVP and CMO	Sold10b5-1 plan	596	$482.50	$288k	3.7%	Form 4
Jun 18	Carmen Bozic EVP and CMO	Sold10b5-1 plan	1,020	$462.17	$471k	6.0%	Form 4
Jun 15	Carmen Bozic EVP and CMO	Sold10b5-1 plan	4,062	$450.00	$1.83M	19%	Form 4
Jun 5	Carmen Bozic EVP and CMO	Sold10b5-1 plan	1,745	$450.00	$785k	7.7%	Form 4
Jun 1	Joy Liu EVP and Chief Legal Officer	Sold10b5-1 plan	828	$439.91	$364k	4.0%	Form 4
May 29	Carmen Bozic EVP and CMO	Sold10b5-1 plan	1,974	$450.00	$888k	8.0%	Form 4
May 15	Mark E. Bunnage EVP, Chief Scientific Officer	Sold10b5-1 plan	33	$453.45	$15k	0.5%	Form 4
May 15	Carmen Bozic EVP and CMO	Sold10b5-1 plan	1,354	$453.45	$614k	5.2%	Form 4
May 12	Carmen Bozic EVP and CMO	Sold10b5-1 plan	6,988	$450.00	$3.14M	21%	Form 4
May 4	Sangeeta N. Bhatia Director	Sold10b5-1 plan	318	$423.73	$135k	6.1%	Form 4
May 1	Joy Liu EVP and Chief Legal Officer	Sold10b5-1 plan	1,104	$425.02	$469k	5.1%	Form 4
Apr 1	Joy Liu EVP and Chief Legal Officer	Sold10b5-1 plan	978	$449.17	$439k	4.3%	Form 4
Mar 27	Carmen Bozic EVP and CMO	Sold10b5-1 plan	2,329	$450.95	$1.05M	6.6%	Form 4
Mar 13	Carmen Bozic EVP and CMO	Sold10b5-1 plan	2,329	$481.79	$1.12M	6.2%	Form 4
Mar 11	Duncan McKechnie EVP, Chief Commercial Officer	Sold10b5-1 plan	2,633	$498.42	$1.31M	17%	Form 4
Mar 4	Duncan McKechnie EVP, Chief Commercial Officer	Sold10b5-1 plan	2,437	$475.30	$1.16M	14%	Form 4
Mar 2	Joy Liu EVP and Chief Legal Officer	Sold10b5-1 plan	892	$495.96	$442k	3.8%	Form 4
Feb 27	Reshma Kewalramani CEO & President	Sold10b5-1 plan 13 parts	40,000	$493.47 average	$19.7M	29%	Form 4
Feb 27	Carmen Bozic EVP and CMO	Sold10b5-1 plan	2,329	$480.31	$1.12M	5.8%	Form 4
Feb 26	Kristen Ambrose SVP & Chief Accounting Officer	Sold10b5-1 plan	357	$483.36	$173k	5.1%	Form 4
Feb 25	Ourania Tatsis EVP, Chief Reg. & Quality Off.	Sold10b5-1 plan	260	$486.35	$126k	0.6%	Form 4
Feb 25	Amit Sachdev EVP Chief Patient & Ext Af Off	Sold10b5-1 plan	1,846	$486.35	$898k	2.7%	Form 4
Feb 25	Duncan McKechnie EVP, Chief Commercial Officer	Sold10b5-1 plan 2 parts	4,910	$487.65 average	$2.39M	22%	Form 4
Feb 25	Mark E. Bunnage EVP, Chief Scientific Officer	Sold10b5-1 plan	620	$486.35	$302k	7.8%	Form 4
Feb 25	Jonathan Biller EVP and Chief Legal Officer	Sold10b5-1 plan	945	$486.35	$460k	6.5%	Form 4
Feb 25	Edward Morrow Atkinson III EVP, Chief Technical Ops. Off.	Sold10b5-1 plan	668	$486.35	$325k	3.5%	Form 4
Feb 25	Kristen Ambrose SVP & Chief Accounting Officer	Sold10b5-1 plan	223	$486.35	$108k	3.1%	Form 4
Feb 19	Amit Sachdev EVP Chief Patient & Ext Af Off	Sold10b5-1 plan 8 parts	58,613	$468.83 average	$27.5M	46%	Form 4
Feb 17 – 18	Ourania Tatsis EVP, Chief Reg. & Quality Off.	Sold10b5-1 plan 2 parts	977	$483.52 average	$472k	2.0%	Form 4
Feb 17 – 18	Mark E. Bunnage EVP, Chief Scientific Officer	Sold10b5-1 plan 2 parts	3,619	$484.31 average	$1.75M	30%	Form 4
Feb 17 – 18	Jonathan Biller EVP and Chief Legal Officer	Sold10b5-1 plan 2 parts	3,720	$484.18 average	$1.8M	19%	Form 4
Feb 17 – 18	Edward Morrow Atkinson III EVP, Chief Technical Ops. Off.	Sold10b5-1 plan 2 parts	2,848	$484.93 average	$1.38M	12%	Form 4
Feb 17 – 18	Kristen Ambrose SVP & Chief Accounting Officer	Sold10b5-1 plan 2 parts	2,195	$484.87 average	$1.06M	22%	Form 4
Feb 13	Ourania Tatsis EVP, Chief Reg. & Quality Off.	Sold10b5-1 plan	1,500	$499.99	$750k	3.1%	Form 4
Feb 13	Jonathan Biller EVP and Chief Legal Officer	Sold10b5-1 plan	988	$499.00	$493k	5.5%	Form 4
Feb 13	Sangeeta N. Bhatia Director	Sold10b5-1 plan	266	$500.00	$133k	5.8%	Form 4
Feb 11	Ourania Tatsis EVP, Chief Reg. & Quality Off.	Sold10b5-1 plan	466	$460.43	$215k	0.9%	Form 4

Jul 210b5-1 plan
Ourania Tatsis
EVP, Chief Reg. & Quality Off. · sold 1,500 at $524.99
$787k
3.2% of stake
Jul 210b5-1 plan
Duncan McKechnie
EVP, Chief Commercial Officer · sold 1,541 at $519.00
$800k
12% of stake
Jul 110b5-1 plan
Joy Liu
EVP and Chief Legal Officer · sold 828 at $502.71
$416k
4.1% of stake
Jun 2610b5-1 plan
Carmen Bozic
EVP and CMO · sold 596 at $482.50
$288k
3.7% of stake
Jun 1810b5-1 plan
Carmen Bozic
EVP and CMO · sold 1,020 at $462.17
$471k
6.0% of stake
Jun 1510b5-1 plan
Carmen Bozic
EVP and CMO · sold 4,062 at $450.00
$1.83M
19% of stake
Jun 510b5-1 plan
Carmen Bozic
EVP and CMO · sold 1,745 at $450.00
$785k
7.7% of stake
Jun 110b5-1 plan
Joy Liu
EVP and Chief Legal Officer · sold 828 at $439.91
$364k
4.0% of stake
May 2910b5-1 plan
Carmen Bozic
EVP and CMO · sold 1,974 at $450.00
$888k
8.0% of stake
May 1510b5-1 plan
Mark E. Bunnage
EVP, Chief Scientific Officer · sold 33 at $453.45
$15k
0.5% of stake
May 1510b5-1 plan
Carmen Bozic
EVP and CMO · sold 1,354 at $453.45
$614k
5.2% of stake
May 1210b5-1 plan
Carmen Bozic
EVP and CMO · sold 6,988 at $450.00
$3.14M
21% of stake
May 410b5-1 plan
Sangeeta N. Bhatia
Director · sold 318 at $423.73
$135k
6.1% of stake
May 110b5-1 plan
Joy Liu
EVP and Chief Legal Officer · sold 1,104 at $425.02
$469k
5.1% of stake
Apr 110b5-1 plan
Joy Liu
EVP and Chief Legal Officer · sold 978 at $449.17
$439k
4.3% of stake
Mar 2710b5-1 plan
Carmen Bozic
EVP and CMO · sold 2,329 at $450.95
$1.05M
6.6% of stake
Mar 1310b5-1 plan
Carmen Bozic
EVP and CMO · sold 2,329 at $481.79
$1.12M
6.2% of stake
Mar 1110b5-1 plan
Duncan McKechnie
EVP, Chief Commercial Officer · sold 2,633 at $498.42
$1.31M
17% of stake
Mar 410b5-1 plan
Duncan McKechnie
EVP, Chief Commercial Officer · sold 2,437 at $475.30
$1.16M
14% of stake
Mar 210b5-1 plan
Joy Liu
EVP and Chief Legal Officer · sold 892 at $495.96
$442k
3.8% of stake
Feb 2710b5-1 plan
Reshma Kewalramani
CEO & President · sold 40,000 at avg $493.47
$19.7M
29% of stake
Feb 2710b5-1 plan
Carmen Bozic
EVP and CMO · sold 2,329 at $480.31
$1.12M
5.8% of stake
Feb 2610b5-1 plan
Kristen Ambrose
SVP & Chief Accounting Officer · sold 357 at $483.36
$173k
5.1% of stake
Feb 2510b5-1 plan
Ourania Tatsis
EVP, Chief Reg. & Quality Off. · sold 260 at $486.35
$126k
0.6% of stake
Feb 2510b5-1 plan
Amit Sachdev
EVP Chief Patient & Ext Af Off · sold 1,846 at $486.35
$898k
2.7% of stake
Feb 2510b5-1 plan
Duncan McKechnie
EVP, Chief Commercial Officer · sold 4,910 at avg $487.65
$2.39M
22% of stake
Feb 2510b5-1 plan
Mark E. Bunnage
EVP, Chief Scientific Officer · sold 620 at $486.35
$302k
7.8% of stake
Feb 2510b5-1 plan
Jonathan Biller
EVP and Chief Legal Officer · sold 945 at $486.35
$460k
6.5% of stake
Feb 2510b5-1 plan
Edward Morrow Atkinson III
EVP, Chief Technical Ops. Off. · sold 668 at $486.35
$325k
3.5% of stake
Feb 2510b5-1 plan
Kristen Ambrose
SVP & Chief Accounting Officer · sold 223 at $486.35
$108k
3.1% of stake
Feb 1910b5-1 plan
Amit Sachdev
EVP Chief Patient & Ext Af Off · sold 58,613 at avg $468.83
$27.5M
46% of stake
Feb 17 – 1810b5-1 plan
Ourania Tatsis
EVP, Chief Reg. & Quality Off. · sold 977 at avg $483.52
$472k
2.0% of stake
Feb 17 – 1810b5-1 plan
Mark E. Bunnage
EVP, Chief Scientific Officer · sold 3,619 at avg $484.31
$1.75M
30% of stake
Feb 17 – 1810b5-1 plan
Jonathan Biller
EVP and Chief Legal Officer · sold 3,720 at avg $484.18
$1.8M
19% of stake
Feb 17 – 1810b5-1 plan
Edward Morrow Atkinson III
EVP, Chief Technical Ops. Off. · sold 2,848 at avg $484.93
$1.38M
12% of stake
Feb 17 – 1810b5-1 plan
Kristen Ambrose
SVP & Chief Accounting Officer · sold 2,195 at avg $484.87
$1.06M
22% of stake
Feb 1310b5-1 plan
Ourania Tatsis
EVP, Chief Reg. & Quality Off. · sold 1,500 at $499.99
$750k
3.1% of stake
Feb 1310b5-1 plan
Jonathan Biller
EVP and Chief Legal Officer · sold 988 at $499.00
$493k
5.5% of stake
Feb 1310b5-1 plan
Sangeeta N. Bhatia
Director · sold 266 at $500.00
$133k
5.8% of stake
Feb 1110b5-1 plan
Ourania Tatsis
EVP, Chief Reg. & Quality Off. · sold 466 at $460.43
$215k
0.9% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch VRTX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Pharmaceutical Preparations

BHCBausch Health Companies Inc.

VTRSViatris Inc.

REGNRegeneron Pharmaceuticals, Inc.

ZTSZoetis Inc.

TEVATeva Pharmaceutical Industries Ltd

UPCUniverse Pharmaceuticals Inc.

ONCBeOne Medicines Ltd.

OGNOrganon & Co.

Spot a number that looks wrong? Check it in VRTX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing VRTX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.